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CACNA1C polymorphisms Impact 
Cognitive Recovery in Patients 
with Bipolar Disorder in a Six-week 
Open-label Trial
Kangguang Lin1,2,3, Guiyun Xu1,2, Lingling Shi3,4,5, Weicong Lu1,2, Lijie Guan1, Huiyi Ouyang1, 
Kun Chen1,2, Yamei Dang1, Libing Zhou3,4,5 & Kwok-Fai So3,4,5,6
Cognitive impairments in bipolar patients deteriorate as the disorder progresses. Little is known about 
whether genetic risks impact cognitive recovery during the course from depression to remission. In 
this six-week open-label trial, we shed light on the impacts of six single nucleotide polymorphisms 
(SNPs) in the calcium voltage-gated channel subunit alpha1 C (CACNA1C) gene on cognitive recovery 
in 192 bipolar patients suffering a major depressive episode (MDE). The primary outcome measures 
were changes in a battery of neuropsychological tests following 6-week treatment. Carriers with 
rs10466907 GT genotype did not significantly improve their executive function total scores on the 
Wisconsin Card Sorting Test after six weeks of treatment compared to the TT genotypes (β = −0.944, 
95% Confidence Interval (CI) = −1.482–−0.405). Moreover, during a MDE carriers with rs58619945 
GG and GA genotypes performed significantly worse than those with AA genotype on the categories 
completed (p = 0.013 and p = 0.001), total errors (p = 0.039 and p = 0.009), and random errors (p = 0.055 
and p = 0.014, respectively). Our data suggest that the tested CACNA1C SNPs may have impacts on 
cognitive recovery from depression.
Cognitive impairments are core features of bipolar disorder (BD). Circumscribed deficits on domains such as 
visual-spatial memory and processing speed were manifested prior to the onset of BD in the relatives of BD 
patients, indicating inherited phenotypes1, 2. Impairments in a wide range of cognitive domains then emerge and 
further deteriorate as the disorder progresses3, 4, negatively affecting the quality of life in people with BD5. The 
number of depressive episodes is positively associated with the severity of cognitive impairments6. It has been 
suggested that cognitive impairments are, at least partly, the sequelae of disease progression, particularly major 
depressive episode (MDE). On average, patients with BD have medium to large effect sizes of cognitive impair-
ments that are variable across cognitive domains3. However, individuals also differed markedly in the extent of 
cognitive dysfunction, with some individuals being as severe as patients with schizophrenia while others retaining 
relatively intact cognitive functioning7. Genetic factors may contribute to such variations particularly during 
those critical periods such as MDE and its subsequent recovery.
Genome-wide association studies (GWAS) have repeatedly reported multiple single nucleotide polymor-
phisms (SNPs) in the alpha 1 C subunit of the L-type voltage-gated calcium channel (CACNA1C) gene linked to 
the risk of BD onset8, 9. Despite this, it is unclear how genetic risks give rise to the psychopathology. It has been 
suggested that genetic vulnerabilities exert effects on brain structure and cognitive mechanisms for mental dis-
orders such as BD and schizophrenia, rather than on specific symptoms10. For instance, the minor allele (i.e. SNP 
rs1006737 G allele) of CACNA1C gene was found to be associated with gray matter changes in the left putamen 
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and the right amygdala and hypothalamus11. It also impacted the activation levels in the prefrontal cortex and 
hippocampus during working memory and emotional memory tasks respectively in patients with BD12, and in 
the left precuneus and inferior frontal gyrus in healthy participants13. At the cognitive level, SNP rs1006737 AA 
genotype of CACNA1C gene was reported to be associated with a wide range of cognitive functions in patients 
with BD, as measured by the Forward Digit Span task, Wisconsin Card Sorting Test, Matrix reasoning task, Trail 
Making tests, and Letter-Number Sequence task14. In addition, a 2-year longitudinal study reported that the AA 
genotype might be associated with scores on a composite cognitive measure subsuming the attentional span, 
sustained attention, selective attention, verbal memory, and working memory domains in bipolar patients, albeit 
among a small sample15.
L-type voltage-gated calcium channel (LTCCs) mediates calcium influx into excitable cells such as neurons, 
shaping neuronal firing and being involved in signaling complexes. Their functions and dysfunctions are related 
to neuronal plasticity, learning and memory, and neuropsychiatric illness16, 17. Rare mutations of CACNA1C 
gene could cause Timothy Syndrome, a syndrome that leads to long QT intervals resulting in early death due to 
cardiac arrhythmias. Patients with Timothy Syndrome are likely to suffer BD and cognitive impairments18. As 
mentioned earlier, the common SNP rs1006737—an intronic SNP whose function is still largely unknown—was 
reported to be associated with variations in cognitive functioning19, although inconsistent results were reported20. 
It is noteworthy that most studies that examined the association of CACNA1C SNPs with cognition so far had 
only investigated SNP rs1006737. Moreover, most of those studies were cross-sectional and focused only on the 
euthymic mood state. However, depressive periods dominate the life time of bipolar patients21, 22 and are thought 
to contribute to the “scar” of cognitive impairment among bipolar patients even when they recover from the 
clinically acute condition6, 23. However, little is known about whether and what genetic risk factors impact the 
cognitive functions during recovering from depression.
Therefore, we aimed to investigate the impacts of six CACNA1C SNPs on cognitive recovery in a six-week 
open label trial for bipolar depression. Apart from the most investigated SNP rs1006737, this study selected SNPs 
based on their potential to affect gene expression and/or regulation. Specifically, based on the 1000 Genome 
Project and HapMap data sets24, we selected rs11062319 and rs10466907 that are located in the 3’untranslated 
region, which might act as the miRNAs binding sites for regulating gene expression. Moreover, rs723672 and 
rs58619945 that are located in the promoter region might function as Transcription Factor Binding sites (TFBS). 
Finally, rs1051375 was suggested to be located at putative exonic splicing enhancer (ESE) sites for SC35 and SF2/
ASF and be associated with treatment response to calcium channel blocker in hypertensive patients with stable 
coronary artery disease25.
We hypothesized that CACNA1C polymorphisms may affect the cognitive recovery after 6 weeks of treatment 
for major depression in bipolar patients. The primary outcome measures were the performance level changes on 
a battery of neuropsychological tests from baseline to week 6 of treatment, including attention, processing speed, 
set shifting, verbal working memory, visual memory, and planning. Secondary analysis was conducted to examine 
whether the SNPs were associated with individual differences in cognitive functioning during an MDE among 
bipolar patients.
Results
Sample characteristics and genotypes distributions. The total sample’s demographic and clinical 
characteristics are described in Table 1. The remission rate (defined as HAM-D scores less than or equal to 7) 
for the intent-to-treat sample was 64.1%. All of the tested SNPs were in Hardy-Weinberg equilibrium except for 
rs1051375. None of the SNPs were in significant linkage disequilibrium (LD) in our sample.
Impact of SNP rs10466907 on cognitive changes. As shown in Table 2, the mixed-effect model 
only found that rs10466907 contributed significantly to cognitive recovery on set shifting measured by WCST 
test. Specifically, on the WCST test, significant differences between the genotypes (GT versus TT genotypes) 
were found in total scores completed (Wald X2 = 11.801, pcorrected = 0.012, β = −0.944), total error (Wald 
X2 = 7.652, pcorrected = 0.066 (puncorrected = 0.006), β = −0.87), and random error (Wald X2 = 5.251, pcorrected = 0.22 
Total Sample Stratified by rs10466907 Stratify by rs58619945
n = 192
GT TT GG GA AA
n = 41 n = 151 n = 54 n = 96 n =      41
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age 31.0 11.8 34.2 13.2 30.2 11.2 30.7 11.2 32.2 12.6 29 10.6
Years of 
educations 11.6 4.2 11.6 4.4 11.6 4.2 11.4 4.3 11.4 4.2 12.5 4
Female, % 42.2 NA 48.8 NA 40.4 NA 42.6 NA 44.8 NA 36.6 NA
HAMD score 
(baseline) 25.9 7.0 26.3 7.2 25.8 6.9 25.1 6.9 26 7.2 26.8 6.7
BPRS score 
(baseline) 38.8 8.6 39.0 7.9 38.8 8.8 38.6 8.2 38.8 8.4 39.3 9.6
YMRS score 
(baseline) 1.6 2.8 1.2 2.1 1.7 3.0 1.1 2.5 1.7 2.5 2.1 3.8
Table 1. Demographic and clinical characteristics for the participants. Abbreviation: NA: not applicable; HAM-
D: Hamilton depression Rating Scale; BPRS: Brief Psychiatric Rating Scale; YMRS: Young Mania Rating Scale.
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(puncorrected = 0.022), β = −0.751), indicating carriers with GT genotype did not significantly improve their set 
shifting functioning after six weeks of treatment for bipolar depression compared with those carriers with TT 
genotypes (GG homozygotes were absent) (Fig. 1).
There were no significant differences after six weeks of treatment between the genotypes in HAM-D scores 
(GT genotype versus TT genotype: 6.4 versus 7.7 scores, F = 0.852, p = 0.357), YMRS scores (1.3 versus 1.1 scores, 
F = 0.076, p = 0.783), or BPRS scores (22.1 versus 22.7, F = 0.343, p = 0.559). The remission rate for patients with 
GT genotype (73.2%) was slightly higher than that for patients with TT genotype (61.6%), but did not reach a 
significant level (X2 = 1.879, p = 0.17).
Comparisons in baseline cognitive measures by genotypes. The MANOVA analysis revealed that 
only SNP rs58619945 had a main effect on baseline neurocognitive measures, including the categories completed 
(F = 6.969, df = 2,149, p = 0.001), total errors (F = 4.690, df = 2,149, p = 0.011), and random errors of WCST 
(F = 3.305, df = 2,149, p = 0.40) (Table 3). Post-hoc comparisons using the Bonferroni corrections showed that 
carriers with GG genotype and GA genotype performed significantly worse than those with AA genotype on the 
categories completed (p = 0.013 and p = 0.001, respectively), total errors (p = 0.039 and p = 0.009, respectively), 
and random errors (p = 0.055 and p = 0.014, respectively).
Domain B S.E
Lower 
95%Cl
Upper 
95%Cl
Wald Chi-
Square P
Processing speed
 WAIS-R symbol coding −0.227 0.176 −0.571 0.117 1.667 0.197
Attention
 WAIS-R digit Forward −0.421 0.269 −0.948 0.106 2.450 0.118
Memory
 Working memory
  WAIS-R digit Backward 0.170 0.265 −0.350 0.690 0.412 0.521
  Visual Memory
  WAIS-R visual reproduction −0.127 0.291 −0.697 0.442 0.192 0.661
Verbal fluency
 Animal naming 0.052 0.239 −0.416 0.520 0.048 0.827
Executive function
 Wisconsin Card Sorting Test
  Categories completed −0.944 0.275 −1.482 −0.405 11.801 0.001
  Total errors −0.870 0.315 −1.487 −0.254 7.652 0.006
Perseverative errors −0.753 0.409 −1.554 0.704 3.388 0.066
  Random errors −0.751 0.328 −1.392 −0.109 5.251 0.022
  Tower of Hanoi total scores 0.187 0.522 −0.836 1.211 0.128 0.720
  Trail Marking Test B −0.128 0.958 −2.328 1.406 0.234 0.628
Table 2. The impact of rs10466907 genotypes on cognitive recovery after six weeks of treatment. Note: CI: 
confidence interval.
Figure 1. Cognitive changes in the Wisconsin Card Sorting Test (WCST) for rs10466907 genotypes. Note: Z 
scores for the different neuropsychological testes were calculated using respective mean and standard deviation 
(SD). WCST1: total scores completed; WCST2: total error; WCST 3: random error. Cognitive changes in the 
Wisconsin Card Sorting Test (WCST) for rs10466907 genotypes. Carriers with rs10466907 GT genotype did 
not significantly improve their cognitive functioning compared with those carriers with TT genotypes after six 
weeks of treatment for bipolar depression.
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Other clinical considerations. To test whether baseline demographic and clinical characteristics may 
account for the differences in cognitive recovery, we compared the following variables across the genotype groups 
stratified by rs10466907 and rs58619945: gender, age, years of education, HAM-D, YMRS, and BPRS scores. 
As shown in Table 1, we did not find any significant effect for either genotype (all p > 0.05). The patterns of the 
prescribed medications across the rs10466907 genotype groups were not significantly different (data not shown).
Discussions. In this six-week open-label trial for treating bipolar depression, we found preliminary evi-
dence that CACNA1C SNP rs10466907 may have impacts on cognitive recovery. Carriers of GT genotype did 
not recover their executive function (i.e. set shifting) compared to TT homozogates after six weeks of treatment. 
The remission rate and depressive symptoms at week 6 were not significantly different between the two genotype 
groups, with the GT genotypes showing a non-significant higher trend in the remission rate, indicating that the 
differences in cognitive recovery was not driven by the clinical remission of depressive symptoms. The differential 
impacts by the SNP on cognitive recovery while bipolar patients were recovering from major depression might 
be related to the cognitive impairment heterogeneity among BD patients. Moreover, during a MDE, carrier with 
rs58619945 G allele (including GG homozygotes and GT heterozygotes) performed significantly poorer than 
those with TT genotype on set shifting, suggesting an effect of this SNP on executive function in patients with 
bipolar depression.
Studies demonstrated the involvement of CACNA1C gene in spatial learning by investigating cognitive defi-
cits in CACNA1C knockout animals using a visible platform version of the Morris water maze and a spatial 
learning labyrinth paradigm26. Moreover, patients with Timothy syndrome (TS), a disease caused by rare exonic 
mutations of CACNA1C gene (e.g. de novo missense mutation G406R), suffered not only cardiac arrhythmia 
but cognitive impairment and features of autism27. Research into the physiology of TS-mutated Ca1.2vα1subunit 
showed that it could lead to the upregulation of tyrosine hydroxylase expression, resulting in dysregulation of 
neurotransmitters norepinephrine and dopamine in depression28. Furthermore, human studies support a role of 
voltage-gated cation channels such as CACNA1C in working memory-related learning in healthy individuals29 as 
well as in psychiatric conditions characterized by cognitive deficits30. Future studies need to investigate whether 
the impact of rs10466907, which might act as an miRNA binding site, was mediated via regulation of CACNA1C 
expression.
We also studied SNP rs1006737, which might be the most-studied SNP in CACNA1C gene so far, but did 
not find any significant associations with cognition. Using the WCST, Soeiro-de-Souza et al. found that bipolar 
patients with AA genotype performed significantly worse than those with GG genotype14. The influences of the 
risk allele on gray matter (GM) changes in regions such as the prefrontal cortex (PFC), anterior cingulate cortex 
(ACC), and temporal cortex were also reported31. Applying diffusion tensor imaging, Dietsche et al. showed an 
association between the risk allele and fractional anisotropy (FA) value, a measure indicative of white matter 
integrity, in the hippocampal formation. In the same bipolar patients, carriers with the risk allele displayed poorer 
Domain and measure
GG GA AA MANOVAa
n = 54 n = 96 n = 41
F p Post-HocbMean SD Mean SD Mean SD
Processing speed
 Trail Marking Test A 55.8 31.0 55.1 25.2 47.7 22.5 0.131 0.877
 WAIS-R symbol coding 39.3 17.9 35.8 16.4 40.8 16.3 0.308 0.736
Attention
 WAIS-R digit Forward 8.0 1.3 7.6 1.6 8.1 1.5 0.742 0.478
Memory
 Working Memory
 WAIS-R digit Backward 4.5 1.6 4.2 1.4 4.5 1.8 0.669 0.514
Visual Memory
 WAIS-R visual reproduction 7.1 3.6 7.0 3.2 8.1 4.1 0.645 0.526
Verbal fluency
 Animal naming 16.5 5.2 15 5.3 15.7 6.1 0.659 0.519
Executive function
 Wisconsin Card Sorting Test
   Categories completed 2.7 2.2 2.5 2.1 4.1 2 6.965 0.001 AA > AG; AA > GG
   Total errors 25.4 12.9 26.1 13.2 18.1 12.7 4.690 0.011
      Perseverative errors 10.6 9.5 11.4 11.4 7.4 9.8 1.832 0.164 AA > AG; AG > GG
   Random error 14.74 7.6 15.14 8.1 10.7 6.5 3.305 0.04 AA > AG
  Trail Marking Test B 97.9 73.5 97.4 47.7 91.9 93.7 0.413 0.662
Tower of Hanoi
  Total scores 42.6 18.9 38 18.7 46 17.8 0.733 0.482
Table 3. Performance on neuropsychological test by bipolar patients stratified by rs58619945 genotypes. Note: 
aMANOVA: Multivariate Analysis of Variance; bp < 0.05 with Bonferroni correction.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:  7022 | DOI:10.1038/s41598-017-07368-5
performance on the Verbal Learning and Memory Test than did those without the allele32. Considering functional 
magnetic resonance imaging (fMRI) studies, Paulus et al. found that healthy individuals with the homozygous 
risk allele displayed decreased activation in the dorsolateral PFC compared to non-risk allele carriers during a 
working memory task33. However, it is estimated that genetic risk variants could have larger effects on the man-
ifestation of the disorder in brain structure and functions compared to cognitive performance measures34. Our 
negative result of rs1006737 was supported by other neuropsychological studies20, 35. However, one main differ-
ence between the present and previous studies is that we specifically tested patients in major depression state. 
Numerous pathophysiologic processes underlie this state, during which bipolar patients suffered more severe 
cognitive impairments compared to when being in euthymic states26, 36. As such, the effect of rs1006737, if any, 
could be overlaid by the influence of such a critical clinical period.
Our findings may have potential implications for understanding the genetic variants underlying the heter-
ogeneous cognitive impairments in bipolar patients which are further deteriorated during depressive episodes. 
Preventing the onset of major depression may be a crucial strategy for preserving cognitive functioning for 
those rs10466907 G allele carriers with BD, given the very limited medications for cognitive impairments for 
BD. Research into the function of the SNP could help elucidate the mechanisms by which it impacts cognitive 
recovery, opening a possibility for developing medications targeting on cognitive impairments. Some open-label 
studies suggest that repetitive transcranial magnetic stimulation (rTMS) may remedy cognitive impairment in 
major depression37. Further studies may be needed to examine whether there are interactions between the two 
SNPs and the intervention effects.
There were some limitations that must be stated. Firstly, this trial was a naturalistic study and medications 
were uncontrolled. As such, the effects of medications on cognitive function and their potential interactions with 
genetic variants could not be assessed. However, it is unlikely that the differential effects of rs10466907 on cogni-
tive recovery were totally driven by medications as the types of medications and their doses were not significantly 
different across the genotype groups. Secondly, it was a convenient sample and the sample size was small. Thirdly, 
the trial was short-term and some patients were still not clinically remitted. As such, it was unclear whether the 
impacts of the rs10466907 on cognitive recovery were sustained in longer periods. Fourth, the association of SNP 
rs58619945 with cognitive impairments might be confounded by clinical and demographic factors.
In summary, CANCA1C SNP rs10466907 may have impact on the cognitive recovery after six weeks of treat-
ment for bipolar depression. Carriers of SNP rs10466907 G allele did not significantly improve their cognitive 
function. For SNP rs58619945, carriers with G allele performed significantly poorer on set shifting compared 
with AA homozygotes during an MDE. Our data suggest the involvement of CACNA1C SNP rs10466907 in 
cognitive recovery during the treatment of depression and an effect of rs5861995 on cognitive impairment during 
major depression.
Methods
Study design and patients. The CBCOB project (Clinical and Biological Characteristics and Optimizing 
treatment in Bipolar Depressive disorder) was a 6-week open-label trial for treating bipolar depression38. The trial 
was conducted in two sites in Guangzhou, China—Guangzhou Brain Hospital, affiliated hospital of Guangzhou 
Medical University39 and The first affiliated hospital of Jinan University. Both hospitals were tertiary medical 
centers (e.g. national clinical centers and University teaching hospitals). The trial was approved by the insti-
tutional review boards and ethics committees of Guangzhou Brain Hospital, registered on 23 November 2010 
at China Clinical Trial (Registration number: ChiCTR-TNRC-10001112). All participants provided written 
informed consent. The methods were performed in accordance with the described procedures in the approved 
study protocol.
The trial enrolled inpatients and outpatients aged 18–60 years who were diagnosed with bipolar I or bipolar II 
disorder and were suffering a MDE, defined by the Diagnostic and Statistical Manual-IV criteria. All of the par-
ticipants were Chinese Han origin. The exclusion criteria included the following conditions: pregnancy, serious 
general medical illness, history of seizure, DSM-IV-TR-defined organic mental disorders, dementia, schizophre-
nia, delusional disorder, schizoaffective disorder, active substance use disorder, and history of mental retardation. 
During the six-week trial, Hamilton depression Rating Scale (HAM-D), Young Mania Rating Scale (YMRS), 
Hamilton Anxiety Rating Scale (HAM-A), and Brief Psychiatric Rating Scale (BPRS) were applied to assess the 
severity of depression, anxiety, hypo/manic and psychotic symptoms, respectively (at week 1, 2, 4, and 6). The 
present study included 192 patients who provided blood samples for genotyping.
Protocol treatments. This was a naturalistic trial attempting at mimicking the real-world clinical practice. 
Patients and clinicians were not blind to treatment assignment. According to the trial protocol, patients were 
treated with one mood stabilizer (i.e lithium, valproate and lamotrigine) and/or an antidepressant that belonged 
to one of the categories including serotonin reuptake inhibitor (SSRIs), serotonin and norepinephrine reuptake 
inhibitors (SNRI) or mirtazapine. Doses were adjusted within normal dosing range by the patient’s treating clini-
cian. Sleep aids were allowed on a short-term basis.
Cognitive assessments and outcome measures. At baseline and week 6, participants completed a bat-
tery of neuropsychological tests that assessed seven cognitive domains, including attention, processing speed, set 
shifting, verbal fluency, verbal working memory, planning, and visual memory. Frist, attention was assessed by the 
Digit Span Forward subtest of the Wechsler Adult Intelligence Scale-Revised by China (WAIS-RC)40. Second, pro-
cessing speed was assessed by the Digit Symbol Coding subtest of the WAIS-RC40. Third, set shifting was assessed 
by the Modified Wisconsin Card Sorting Test (WCST-M)41. Fourth, verbal fluency was assessed by the animal 
naming test42. Fifth, verbal working memory was assessed by the Digit Span Backward subtest of the WAIS-RC40. 
Sixth, planning was assessed by the Tower of Hanoi (TOH)43. Finally, visual-spatial memory was assessed by the 
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Immediate Visual Reproduction subtest of the Wechsler Memory Scale-Revised by China (WMS-RC)44. Patients 
were free of medications when being administered the cognitive assessments at baseline as they were either newly 
diagnosed cases or had discontinued psychiatric medications for at least two weeks. The primary outcome meas-
ures used in this trial were changes in the neurocognitive scores from baseline to week 6 of treatment.
Genotyping. We genotyped six SNPs in or near the CACNA1C gene which were chosen based on their pre-
viously reported potentials to affect gene expression/regulation as mentioned earlier. These SNPs were rs1006737, 
rs1051375, rs10466907, rs11062319, rs723672, and rs58619945. The LD matrix between these SNPs and their 
positions on chromosome are shown Fig. 2.
Genomic DNA was extracted from whole blood according to standard procedures. Investigation of the SNPs 
was performed on the commercially available Sequenom MassARRAY platform. The six SNPs were simultane-
ously identified by a genotyping technology called iPLEX Gold (Sequenom) followed by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis45, 46.
Statistical analysis. Plink 1.07 was used to establish a Hardy-Weinberg test statistics for each SNP 
(alpha = 10e-5) and to calculate pairwise LD between the SNPs. Neurocognitive measures with inverse scale 
properties were back-inverted so that higher scores indicated better performance. Demographic and clinical var-
iables were compared among genotype groups using Chi-square test or one-way analyses of variance (ANOVA) 
where appropriate.
To test the effect of CACNA1C SNPs on changes in cognitive function, we used a mixed-effect regression 
model with unstructured covariance to model a 6-week change in cognitive performance by the CACNA1C 
SNPs tested. Each of the twelve neurocognitive measures was z-transformed using respective mean and stand-
ard deviation (SD) for the ease of comparisons. The model adjusted for the following variables: gender, age, 
years of education, depressive symptoms at baseline, psychotic symptoms at baseline, and medication (types of 
Figure 2. Linkage disequilibrium matrix of the studied CACNA1C SNPs rs1006737, rs1051375, rs723672, 
rs10466907, rs11062319, and rs58619945 in Han Chinese in Beijing, China. Note: CACNA1C: calcium voltage-
gated channel subunit alpha1 C; SNPs: single nucleotide polymorphisms.
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antidepressant and antipsychotics). We excluded rs1006737 and rs11062319 in the following analysis because 
the frequency of minor allele (A allele = 2.9%; C allele = 2.7%, respectively) was less than 5%. As such, four 
SNPs in total were included in the analyses. Wald statistic (W) was applied to determine the significance of 
each predictor. To account for the multiple statistical testing, we set the significance level of p < 0.0125 for the 
four SNPS (Bonferroni corrections, 0.05/4 = 0.0125). Holm-Bonferroni method47 was further performed for the 
multiple-testing of the 12 neurocognitive measures with a significance level of p < 0.0125. As it is possible that 
such stringent significance level may produce unwanted false negatives, we also reported uncorrected significant 
effects (p < 0.05) for completeness.
To test the association of CACNA1C polymorphisms with cognitive function during a MDE, multivariate 
analysis of variance (MANOVA) was applied to compare neuropsychological measures at baseline among geno-
type groups, adjusting for gender, age, years of education, depressive symptoms at baseline, and psychotic symp-
toms at baseline. In order to reduce multiple statistical testing, all tested SNPs were simultaneously entered into 
the MANOVA model as fixed factors. Bonferroni corrections for multiple comparisons were applied in post-hoc 
testing with a significance level of p < 0.05.
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